Drug Trial Radar · NCT07773246
Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 28, 2026
Primary completion
Aug 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Korro Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase 1/2 Study of KRRO-121 is a randomized, placebo-controlled study in Healthy Volunteers (Phase 1 SAD and MAD) and Study Participants with Urea Cycle Disorders (Phase 2). The primary objective of the study is to evaluate the safety of KRRO-121.
Conditions
- Urea Cycle Disorders, Inborn
- Urea Cycle Disorders
- Ornithine Transcarbamylase (OTC) Deficiency
- Arginase 1 Deficiency
- NAGS Deficiency
- Carbamylphosphate Synthetase I
- Ornithine Transporter Mitochondrial 1
- Argininosuccinate Synthase
- Argininosuccinate Lyase Deficiency
- N-acetyl Glutamate - Synthetase
- Citrin Deficiency
Interventions
KRRO-121Drug
KRRO-121, subcutaneous injection
PlaceboDrug
Placebo, subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLT) (Safety and Tolerability)Time frame: Day 1 through 14 days post-dose
- Frequency and severity of treatment-emergent adverse events (TEAEs; per Common Terminology Criteria for Adverse Events [CTCAE]) (Safety and Tolerability)Time frame: Day 1 through Day 50
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.